Quarterly ResultMay 15, 2026, 08:07 AM
aTyr Pharma to advance efzofitimod to Phase 3; Q1 Net Loss $(10.8)M
AI Summary
aTyr Pharma announced its first quarter 2026 financial results and provided a corporate update, highlighting a clear path forward for efzofitimod in pulmonary sarcoidosis following a Type C meeting with the FDA. The company plans to submit an IND in June 2026 for a new Phase 3 study for efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis. Additionally, aTyr Pharma is on track to complete enrollment in its Phase 2 EFZO-CONNECT™ study for SSc-ILD in the first half of 2026. The company reported a net loss of $(10.8) million for the quarter, with $68.3 million in cash and investments.
Key Highlights
- Plans to submit IND in June 2026 for Phase 3 study of efzofitimod in pulmonary sarcoidosis.
- On track to complete enrollment in Phase 2 EFZO-CONNECT™ study for SSc-ILD in H1 2026.
- Ended Q1 2026 with $68.3 million in cash, cash equivalents, and investments.
- Reported Q1 2026 net loss of $(10.8) million, compared to $(14.9) million in Q1 2025.
- Net loss per share was $(0.11) for Q1 2026, compared to $(0.17) in Q1 2025.
- Research and development expenses decreased to $7.3 million in Q1 2026 from $11.8 million in Q1 2025.
- General and administrative expenses were $4.1 million in Q1 2026, up from $4.0 million in Q1 2025.
Price Impact
More from ATYR